Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke device could revolutionize heart attack treatment

NCT ID NCT05307965

Disease control Sponsor: Oxford University Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a stent retriever device, already used for strokes, to remove clots during heart attacks. The goal was to reduce damage to small heart blood vessels caused by clot fragments. 81 patients with severe heart attacks were enrolled to see if the device works better than standard clot removal methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stent retriever device (SolitaireTM X Revascularisation Device)
What this could lead to
If it works, this could offer a better way to remove clots during heart attacks, potentially reducing long-term heart damage and improving recovery.
What could go wrong
This is a small, early-stage trial with only 81 participants. The device may not work better than standard care, and there are risks like vessel damage or complications during the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

81 people

The number who actually took part.

Started

May 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary PCI patient with ST elevation myocardial infarction (STEMI) * TIMI 0/1 flow at presentation * Angiographic thrombus score ≥ 4 * Vessel diameter at site of occlusion ≥ 3.0 mm (measured by quantitative coronary angiography) Exclusion Criteria: * Female participant who is pregnant or lactating * Participant with known hypersensitivity to nickel-titanium * Unconscious at presentation * Late presenter (pain to wire time \> 12 h) * Class Killip III/IV and/or profound bradycardia (Heart rate \< 40 bpm) * Known history of kidney failure * Ostial occlusion * Highly tortuous vessel * Highly calcified vessel * Suspected (angiographically) spontaneous coronary artery dissection * Stent thrombosis * Previous stent implanted proximal to the occlusion site * Previous coronary artery bypass graft surgery (CABG) * Previous STEMI/Transient Ischemic Attack/Stroke * Known anaemia (Hemoglobin \<9)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction ST-elevation myocardial infarction thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Myocardial infarction Thrombus

Contacts and locations

Locations

  • Oxford Heart Centre

    Oxford, OX3 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.